You are here: Industry Insights > Evox Therapeutics

News List

University of Oxford links up with Evox Therapeutics pharmatimes
November 19, 2020
The University of Oxford’s Harrington Rare Disease Centre has entered a strategic collaboration agreement with Evox Therapeutics focused on rare diseases within the Department of Paediatrics.
Lilly signs up for access to Evox' tech in R&D deal pharmatimes
June 16, 2020
Evox Therapeutics has signed a collaboration deal with Eli Lilly centred on brain/CNS disorders, which could net the latter around $1.2 billion in development, regulatory and commercial milestone payments.
Evox and Takeda sign deal to collaborate on rare disease treatments europeanpharmaceuticalreview
April 02, 2020
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
Takeda enters rare disease alliance with Evox Therapeutics pharmaceutical-technology
March 30, 2020
Takeda Pharmaceutical has entered a multi-target alliance with biotechnology company Evox Therapeutics to develop protein replacement and mRNA therapies for rare diseases.